List of Excipients in Branded Drug ALOSETRON HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	ALOSETRON HYDROCHLORIDE	alosetron hydrochloride	45963-479	CELLULOSE, MICROCRYSTALLINE
Actavis Pharma Inc	ALOSETRON HYDROCHLORIDE	alosetron hydrochloride	45963-479	HYPROMELLOSES
Actavis Pharma Inc	ALOSETRON HYDROCHLORIDE	alosetron hydrochloride	45963-479	LACTOSE
Actavis Pharma Inc	ALOSETRON HYDROCHLORIDE	alosetron hydrochloride	45963-479	MAGNESIUM STEARATE

Generic Drugs Containing ALOSETRON HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	alosetron hydrochloride	0054-0295	ANHYDROUS LACTOSE
West-Ward Pharmaceuticals Corp	alosetron hydrochloride	0054-0295	CELLULOSE, MICROCRYSTALLINE
West-Ward Pharmaceuticals Corp	alosetron hydrochloride	0054-0295	MAGNESIUM STEARATE
West-Ward Pharmaceuticals Corp	alosetron hydrochloride	0054-0295	STARCH, CORN

What are the Most Frequently-Used Excipients in ALOSETRON HYDROCHLORIDE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE
3	HYPROMELLOSE 2910
3	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for Alosetron Hydrochloride

Last updated: February 28, 2026

What are the primary excipient considerations for Alosetron Hydrochloride?

Alosetron Hydrochloride is a selective serotonin 4 receptor agonist indicated for irritable bowel syndrome with diarrhea (IBS-D). Its formulation demands excipients that enhance stability, bioavailability, and patient compliance.

Common excipients include:

• Binders: Microcrystalline cellulose, which ensures tablet integrity.
• Disintegrants: Crospovidone or croscarmellose sodium, facilitating rapid dissolution.
• Fillers/diluents: Lactose or calcium carbonate, adjusting tablet weight.
• Lubricants: Magnesium stearate, preventing adhesion during compression.
• Coatings: Hydroxypropyl methylcellulose (HPMC), controlling release profile and masking taste.

Formulation complexities depend on the desired release characteristics—immediate-release versus controlled-release formats.

How do excipient choices impact formulation development?

Excipient selection influences:

• Stability: Compatibility with active pharmaceutical ingredient (API) prevents degradation.
• Bioavailability: Solubility enhancement via excipients that improve dissolution.
• Manufacturability: Flow properties affect tablet compression and shape integrity.
• Patient compliance: Excipients like flavoring agents improve palatability for oral formulations.

For Alosetron Hydrochloride, stability studies verify excipient compatibility because moisture-sensitive excipients like lactose can impact shelf life. Controlled-release formulations may incorporate hydrophilic swellable polymers to extend dosing intervals, improving adherence.

What are commercial opportunities related to excipient strategies?

Key opportunities include:

• Optimized formulations for market differentiation: Developing extended-release versions can command premium pricing.
• Platform technology licensing: Proprietary excipient systems can create barriers to competitors.
• Supply chain partnerships: Securing reliable sources of specialized excipients (e.g., high-purity HPMC) reduces risk.
• Regulatory advantages: Using excipients with established safety profiles (generally recognized as safe, GRAS) eases approval processes.
• Cost reduction: Bulk procurement of common excipients decreases production expenses.

Manufacturers can leverage excipient innovations, such as taste-masking agents or moisture barriers, to enhance product appeal in competitive IBS therapies.

Are there regulatory considerations impacting excipient strategies?

Regulatory authorities prioritize safety and consistency. For Alosetron Hydrochloride, excipients must meet specifications outlined in pharmacopeias (USP, EP). Novel excipients or new uses of existing excipients require rigorous documentation of safety, stability, and manufacturing controls.

Incorporating well-characterized excipients supports streamlined regulatory approval, enabling faster time-to-market.

How does excipient strategy influence commercialization?

Effective excipient choices improve:

• Formulation robustness: Reduces batch failures and delays.
• Product differentiation: Novel release profiles or taste-masking can differentiate products.
• Patient adherence: Palatable, easy-to-swallow formulations increase compliance.
• Global market acceptance: Use of globally recognized excipients simplifies regulatory pathways across regions.

Investments in excipient research and supply chain security can yield cost advantages and reduce commercialization timelines.

Key Takeaways

• Excipient selection for Alosetron Hydrochloride balances stability, bioavailability, manufacturability, and patient preference.
• Formulation innovations like sustained release or taste masking expand market opportunities.
• Regulatory compliance hinges on thorough documentation of excipient safety and compatibility.
• Commercial success depends on excipient strategy aligned with product differentiation, supply chain reliability, and cost control.

FAQs

1. What are the most common excipients in Alosetron Hydrochloride formulations?

Microcrystalline cellulose (binder), croscarmellose sodium (disintegrant), lactose (filler), magnesium stearate (lubricant), and HPMC (coating).

2. How does excipient choice affect the stability of Alosetron Hydrochloride?

Excipients influence moisture content and chemical interactions. Compatibility studies are essential to avoid degradation pathways.

3. Can novel excipients provide competitive advantages?

Yes, such as taste-masking agents or controlled-release polymers that improve patient experience and product differentiation.

4. What regulatory challenges are associated with excipient use in Alosetron Hydrochloride?

Compliance with pharmacopeia standards, safety data submission for novel excipients, and demonstrating compatibility are key.

5. How can excipient strategy support global commercialization?

Using excipients with established safety profiles and supply chains facilitates regulatory approval and reduces manufacturing complexities.

---

References

[1] U.S. Pharmacopeia. (2022). USP–NF General Chapters <1074>, <1079>. US Pharmacopeia Convention.

[2] European Pharmacopoeia. (2022). Monographs on excipients. European Directorate for the Quality of Medicines & Healthcare.

[3] Food and Drug Administration (FDA). (2019). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.